WGSGeneDx Holdings Corp
WGS
GeneDx Holdings Corp4,542
Mkt Cap
$1.91BVolume
3.03M52W High
$170.8752W Low
$55.17PE Ratio
-88.11WGS Fundamentals
Price
$67.93Prev Close
$65.38Open
$65.1250D MA
$71.44Beta
1.43Avg. Volume
599,933.75EPS (Annual)
-$0.7339P/B
6.20Rev/Employee
$328,876.15$3,667.03
Compact View
Not available
Not available
Poll
Earnings Recap
• Reported GAAP EPS of -$2.16 down -839.13% YoY • Reported revenue of $102.25M up 17.38% YoY • GeneDx updated its full-year 2026 revenue guidance to $475M to $490M, a reduction from previous guidance, while maintaining expectations for at least 30% exome and genome volume growth.
Bullish
GeneDx achieved strong 34% exome and genome volume growth, expanded Medicaid coverage for 4.9M patients, and demonstrated clinical leadership with 18 pioneering research pieces.
Bearish
GeneDx lowered its full-year 2026 revenue guidance and reported an adjusted net loss of $8.2 million, contrasting with prior year income, alongside a significant impairment loss.